Top > >Company Overview
Company Overview
|
Our lead product candidate, F647, for the treatment of radiation-induced pulmonary inflammation (radiation pneumonitis) and idiopathic pulmonary fibrosis, has completed Phase II clinical trials in China. The IND for our second product, F351, a treatment for liver fibrosis/cirrhosis, has been approved by the State Food and Drug Administration of China and is in Phase I clinical studiesWe also hold a broad portfolio of proprietary technologies that facilitate our drug discovery effort. An integrated platform, including wet-lab drug target validation, computer-aided drug design, and extensive animal model studies have been built up in Shanghai. Our research results have been published in the world's leading scientific journals, such as the Proceedings of the National Academy of Sciences, USA. Extensive research capabilities also enable us to establish research collaborations with international pharmaceutical companies.
Our primary focus is on the development of drugs that treat the broad range of conditions associated with inflammation and cancer. These conditions are particularly prevalent in Asia and result in severe morbidity and mortality among patients. We are committed to developing drugs that will alleviate pain and treat symptoms for which no such drugs yet exist. Our Western-standard integrated drug development program in China provides the infrastructure to support our ongoing therapeutic development.